Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Accounts Payables: 2020-2024

Historic Accounts Payables for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $38.6 million.

  • Apellis Pharmaceuticals' Accounts Payables fell 9.66% to $38.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.6 million, marking a year-over-year decrease of 9.66%. This contributed to the annual value of $38.6 million for FY2024, which is 2.81% up from last year.
  • According to the latest figures from FY2024, Apellis Pharmaceuticals' Accounts Payables is $38.6 million, which was up 2.81% from $37.5 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Accounts Payables ranged from a high of $38.6 million in FY2024 and a low of $8.5 million during FY2020.
  • Moreover, its 3-year median value for Accounts Payables was $37.5 million (2023), whereas its average is $37.8 million.
  • Data for Apellis Pharmaceuticals' Accounts Payables shows a peak YoY surged of 120.84% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Apellis Pharmaceuticals' Accounts Payables stood at $8.5 million in 2020, then soared by 99.47% to $16.9 million in 2021, then soared by 120.84% to $37.3 million in 2022, then increased by 0.47% to $37.5 million in 2023, then rose by 2.81% to $38.6 million in 2024.